A growing number of people with stage 4 cancer are experiencing the power of this new medication. “It does provide options ...
July 7 (Reuters) - The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' ...
A new "tumor-on-a-chip" model is giving scientists a live look at how pancreatic cancer can recruit the body's own immune ...
Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® ...
Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation ...
Morning Overview on MSN
A pancreatic cancer pill let patients live about six months longer than chemotherapy in a trial
Patients with previously treated metastatic pancreatic cancer who took a daily oral drug called daraxonrasib lived a median ...
New experimental pill, daraxonrasib, nearly doubled survival in metastatic pancreatic cancer patients, offering hope for a ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.
Dr. Kyaw Zin Thein was in the middle of a difficult conversation. His patient — a man in his 70s — was running out of options ...
Increased MMP12 levels are associated with a higher risk for pancreatic cancer, especially among patients diagnosed within 4 ...
Researchers tested experimental PCAI compounds against pancreatic cancer cells carrying KRAS mutations. One leading compound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results